Abstract: The present disclosure relates to methods and systems for assessing the risk of a human male subject for developing prostate cancer.

Abstract: The present disclosure relates to methods and systems for assessing the risk of a human female subject for developing breast cancer.

Abstract: The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection.

Abstract: The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection.

Abstract: The present invention relates to methods and systems for assessing the overall risk of a human female subject for developing a breast cancer phenotype. In particular, the present invention relates to combining clinical risk assessment and genetic risk assessment to improve risk analysis.

Abstract: The present invention relates to methods for identifying variations that occur in the human genome and relating these variations to the genetic basis of disease and drug response. In particular, the present invention relates to identifying individual SNPs, determining SNP haplotype blocks and patterns, and, further, using the SNP haplotype blocks and patterns to dissect the genetic bases of disease and drug response. The methods of the present invention are useful in whole genome analysis.

Abstract: The present disclosure relates to methods and systems for assessing the risk of a human female subject for developing breast cancer. In particular, the present disclosure relates to combining clinical risk assessment and genetic risk assessment to improve risk analysis.

Abstract: The present disclosure relates to methods and systems for assessing the risk of a human female subject for developing breast cancer. In particular, the present disclosure relates to combining clinical risk assessment and genetic risk assessment to improve risk analysis.

Abstract: The present invention relates to methods and systems for assessing the overall risk of a human female subject for developing a breast cancer phenotype. In particular, the present invention relates to combining clinical risk assessment and genetic risk assessment to improve risk analysis.

Abstract: The present invention relates to a method of enriching fetal nuclei from a sample. Enriched fetal nuclei can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing.

Abstract: The present disclosure relates to methods and systems for assessing the risk of a human female subject for developing breast cancer. In particular, the present disclosure relates to combining clinical risk assessment and genetic risk assessment to improve risk analysis.

Abstract: A sampling device adapted for transcervical sampling of biological materials from a pregnant patient comprising: an elongate insertion tube (4) having a first end (5) adapted for insertion through the external orifice (external os) of said patient's cervix and a second end (6) including a handle means (7) for manipulating said tube; a measuring means for determining the position of said first end of said tube within said cervix, wherein said first end (5) includes a sampling head (9, 14) adapted to collect biological material including cells, mucus and biological fluids, and wherein said measuring means is adapted to determine the extent of insertion and transcervical position of said first end to optimize the transcervical sampling site.

Abstract: A sampling device adapted for transcervical sampling of biological materials from a pregnant patient comprising: an elongate insertion tube (4) having a first end (5) adapted for insertion through the external orifice (external os) of said patient's cervix and a second end (6) including a handle means (7) for manipulating said tube; a measuring means for determining the position of said first end of said tube within said cervix, wherein said first end (5) includes a sampling head (9, 14) adapted to collect biological material including cells, mucus and biological fluids, and wherein said measuring means is adapted to determine the extent of insertion and transcervical position of said first end to optimise the transcervical sampling site.

Abstract: Embodiments relate generally to a sampling device adapted for sampling of biological materials from a subject and methods of use or manufacture of such devices, as well as diagnostic methods employing such devices and kits including such devices. The sampling device may comprise: an outer tube; an elongate insertion member having a first end and a second end, wherein the first end is distal of the second end, the insertion member being received in and sized to be movable through the outer tube; a coupling portion disposed at the first end of the insertion member; and a sampling portion coupled to the coupling portion and configured to collect the biological materials. The coupling portion is separable from the insertion member.

Abstract: The present invention relates to methods of enriching fetal cells from a pregnant female. The present invention relates to removing, from a sample, cells that comprise at least one MHC molecule. The present invention also relates to methods that rely on using telomerase, mRNA encoding components thereof, as well as telomere length, as markers for fetal cells. Enriched fetal cells can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing.

Abstract: The present invention relates to the identification of fetal specific nucleic acids and fetal cell markers in maternal plasma or serum. In particular, the present invention relates to methods which rely on the analysis of polymorphic alleles of a population to determine an allele which is possessed by the fetus but absent from the mother. Fetal specific alleles identified using the methods of the invention can be used to quantify fetal DNA from maternal plasma or serum. In addition, antigens encoded by alleles identified using the methods of the invention can be targeted in methods of isolating or detecting fetal cells.

Abstract: This application relates to methods for enriching DNA from a first cell type from a sample comprising DNA from the first cell type and DNA from a second cell type, wherein the first cell type methylates DNA to a lesser extent than the second cell type. DNA is enriched by, selecting for fragments by size after digestion of the sample with a methylation-sensitive restriction enzyme. Cell types of interest include fetal cells and cancerous cells. The enriched DNA can be used for a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing.

Abstract: The present invention relates to a method of enriching free fetal nucleic acids from a cervical sample. The enriched fetal nucleic acids can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing.

Abstract: The invention relates to methods for genetic analysis of DNA sequences containing complementary duplicons which are duplicated and linked DNA sequences separated by an intermediate sequence. Furthermore, the invention relates to the Bidirectional Amplification of Complementary Duplicons (BACD) using a single primer. The amplification of complementary duplicons can be used for a variety of purposes such as, determining the species from which a genomic DNA sample is derived, or used as a marker for a trait of interest. Also provided are methods for analyzing large datasets which can be used to identify primers useful for the genomic analysis methods of the invention.

Abstract: The present invention relates to a method of enriching fetal nuclei from a sample. Enriched fetal nuclei can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing.